PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
Brian I. Rini, MD, FASCO - Optimizing Patient Outcomes in RCC Through Safe and Efficacious Use of Immuno-Oncology and Targeted Approaches: Teaming Up to Mitigate and Manage Adverse Events and Maximize Survival
Go online to PeerView.com/BZT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in renal cell carcinoma discusses the latest efficacy and safety data on new treatment approaches, including tyrosine kinase inhibitors, immune checkpoint inhibitors, and novel combination approaches; applying new clinical trial evidence to the selection and sequencing of combination therapies; and mitigating and managing adverse events related to targeted and immune-based therapies to optimize outcomes. Upon completion of this activity, participants will be able to: Summarize the latest efficacy and safety data on new treatment approaches for advanced renal cell carcinoma (RCC), including tyrosine kinase inhibitors, immune checkpoint inhibitors, and novel combination approaches, Apply new clinical trial evidence to the selection and sequencing of combination therapies for individual patients with advanced RCC across lines of therapy, taking into account patient- and disease-related factors, patient values and preferences, and other considerations, Employ effective strategies to proactively mitigate and manage adverse events related to targeted and immune-based therapies for advanced RCC in order to optimize outcomes.